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Smoking cessation
Editor, – It was with considerable disappointment that I read 
J. Litt's contribution 'What's new in smoking cessation?' 
(Aust Prescr 2005;28:73–5). Nothing the author reviewed 
was new. The only truly new development in the field of 
smoking cessation has been the anti-nicotine vaccine. This 
did not seem to get a mention in the article at all. A lot of 
experimental research in animals has been published since 
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Dr John Litt, the author of the article, comments:
Nicotine is the main addictive agent in cigarettes.1 A nicotine 
vaccine offers an additional therapeutic option to reduce the 
likelihood of relapse in smokers who have recently quit. Its 
role in assisting cessation or preventing the development of 
nicotine addiction remains speculative.2
Animal models have shown proof of concept.3 Specifically, 
vaccination with a nicotine conjugate vaccine in mice 
produces antibodies that prevent nicotine crossing 
the blood-brain barrier. The vaccine also prevents the 
nicotine stimulation of dopamine release in the nucleus 
acumbens. This pathway is the postulated pleasure/reward 
pathway associated with various addictions, including 
nicotine. Blocking significant nicotine uptake in the brain 
reduces the rapid gratification effect and interrupts the 
subsequent reward provided by smoking. The process is 
not compromised by concomitant nicotine administration, 
suggesting that the vaccine may have a role in cessation. 
The first phase I study was only published in July 2005.4 
After being immunised with a nicotine vaccine conjugated 
with bacteriophage Qb virus-like particles, 32 volunteers 
had significant increases in nicotine-specific IgM and IgG 
titres at 7 and 14 days respectively. Local reactions including 
erythema, local swelling and tenderness were common 
(88–100%) and a variable number (13–38%) experienced  
flu-like symptoms 2–12 hours post-injection.
A phase II trial is currently underway to assess vaccine 
efficacy. This and subsequent phase II studies will need to 
address a number of unknowns. For example, it is possible 
that the smoker may be able to alter their inhalation of 
nicotine and overcome the relative blockade of nicotine 
uptake into the brain.5 How many boosters are required? 
What is the duration of immunity? What longer-term 
adverse effects are there? Most investigators agree that the 
anti-nicotine vaccine, if shown to be efficacious, will only 
provide an adjunct to counselling and other strategies, for 
example referral to an active callback program offered by 
state Quitlines.2,5 A vaccine is unlikely to assist the patient 
in overcoming the habit of smoking or provide a coping 
strategy for dealing with negative emotions.
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Upper gastrointestinal haemorrhage
Editor, – In the article 'Management of acute bleeding in 
the upper gastrointestinal tract' (Aust Prescr 2005;28:62–6), 
the authors say that an infusion of a high-dose proton 
pump inhibitor for 72 hours is recommended and they give 
the dosing recommendation for omeprazole.1 Recently, 
AstraZeneca has discontinued the intravenous preparation of 
omeprazole, replacing it with esomeprazole. Consequently, 
we wish to comment on the choice of proton pump inhibitor 
now that omeprazole is unavailable. 
Almost all clinical trials evaluating continuous infusion in 
acute gastrointestinal bleeding have used omeprazole. The 
efficacy of other proton pump inhibitors in equivalent doses 
is unproven. There are no published trials directly comparing, 
for example, intravenous omeprazole and pantoprazole for 
nonvariceal acute upper gastrointestinal bleeding. There is a 
study of healthy people, uninfected by Helicobacter pylori, 
which compared intravenous esomeprazole 40 mg with 
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pantoprazole 40 mg once daily. It showed that esomeprazole 
provides faster and more pronounced control of intragastric 
acidity.2 We are unaware of any published studies on the use 
of continuous infusion of esomeprazole.
Esomeprazole is the S-enantiomer of omeprazole and has 
the same pharmacological activity.3 The major difference 
between the enantiomers is in their pharmacokinetics. After 
equivalent doses, esomeprazole reaches higher plasma 
concentrations.4 The manufacturer has provided unpublished 
data based on a study in healthy volunteers comparing the 
effects of various regimens of esomeprazole on maintaining 
intragastric pH > 4 and pH > 6. The results showed that 
intravenous esomeprazole 80 mg when given as an initial 
bolus dose over 30 minutes, followed by a continuous 
infusion of 8 mg/hr, maintained intragastric pH > 4 and pH > 6 
for longer during a 24-hour period than other dosages. 
Given the limited data that are available, we are 
recommending esomeprazole when continuous infusions 
are necessary, until further evidence becomes available. The 
dosage for esomeprazole should follow those suggested for 
continuous infusions of omeprazole, with an initial 80 mg 
dose given over 30 minutes, followed by continuous infusion 
of 8 mg/hr (at a concentration of 0.4 mg/mL) over 72 hours.5
Shin Choo
Pharmacist, The Alfred Hospital 
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Professor R.J. Fraser, one of the authors of the article, 
comments: 
As mentioned in our article, the current standard for 
pharmacological treatment for non-variceal upper 
gastrointestinal haemorrhage is intravenous omeprazole or 
equivalent. Omeprazole has been the proton pump inhibitor 
studied in the majority of published clinical trials, but a small 
number have involved other drugs.1 Esomeprazole, which 
will soon replace omeprazole, obviously fulfils the criteria of 
equivalence, but it is unlikely to be the only drug to do so. 
Esomeprazole is an enantiomer, with theoretical benefits in 
terms of metabolism, but to date this has not been shown 
to provide significant overall benefits compared to racemic 
preparations.
Many clinicians believe the benefits in gastrointestinal 
haemorrhage result from a class effect, with the rise in 
intraluminal pH and resultant clot stability the key to 
improved outcome. The exact parameters that determine clot 
stability and the speed with which these need to be attained 
are unknown. The unpublished data reporting superior 
acid control in healthy volunteers are likely to have limited 
relevance to patient therapy. Although drug potency and the 
speed of acid suppression are clearly important, using these 
unpublished data to infer benefit in patient management is 
unjustified. More data are required in patients before making 
definite recommendations. For economic reasons, and in the 
absence of comparative randomised clinical trials in patients 
with gastrointestinal haemorrhage, clinicians frequently 
prescribe alternatives to omeprazole. Until such trials are 
done, the selection of proton pump inhibitor will continue 
to be a balance between cost, potential benefits and ease of 
administration in the face of incomplete evidence.
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Biochemical tests in pregnancy
Editor, – In addition to the tests mentioned in the article 
'Abnormal laboratory results: Biochemical tests in pregnancy' 
(Aust Prescr 2005;28:98-101), there are several other tests 
where the changes in the normal ranges during pregnancy 
are of clinical importance.
■ Serum bicarbonate falls by approximately 4 mmol/L to 
compensate for the respiratory alkalosis which results 
from elevated progesterone concentrations stimulating 
respiratory drive.1
■ Serum vitamin B12 falls in 25% of pregnant women 
such that a value of greater than 100 pmol/L should be 
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regarded as normal for pregnancy. In the absence of folate 
deficiency serum homocysteine is of value in establishing 
true B12 deficiency in pregnancy.
2,3
■ Erythrocyte sedimentation rate rises significantly (often up 
to 100 mm/hour).4
■ White cell count rises due to neutrophil leucocytosis.5
■ D-dimer becomes elevated in second and third 
trimesters.6
■ Free protein S concentrations fall significantly.7
■ Creatine kinase (MB subfraction) rises after vaginal delivery.8
■ Serum troponin may be elevated in pre-eclampsia making 
diagnosis of myocardial ischaemia problematic if mothers 
develop pulmonary oedema.9
■ Plasma renin activity and serum aldosterone rise masking 
detection of primary aldosteronism as a cause of pre-
gestational hypertension in pregnancy.10
Adam Morton
Senior staff specialist, Endocrinology and Obstetric Medicine
Mater Adult Hospital 
Brisbane
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Dr H.A. Tran, author of the article, comments:
Dr Morton's comments on other laboratory parameters 
that change during pregnancy are very much appreciated. 
The article aimed to highlight biochemical changes in 
common tests without being overly exhaustive. Generally 
speaking, pregnancy is a volume retentive, prothrombotic 
and nutritionally challenged state which results in all the 
corresponding changes described.
The hypervolaemic state is the result of an activated renin-
angiotensin system with markedly elevated aldosterone 
concentrations and plasma renin activity. The normal 
physiological control of this system however remains intact, 
distinguishing it from primary hyperaldosteronism during 
pregnancy.1 
The prothrombotic state is highlighted by the elevated 
d-dimer concentrations and reduced free protein S 
concentrations. The latter is the result of elevated protein 
binding capacity which is typical of pregnancy. Similarly, 
elevated transcobalamin and haptocorrin concentrations 
contribute to the reduction in cobalamin concentrations2 
although preferential fetal transfer during pregnancy also 
adds to the problem, particularly in vegans. It is probably 
more cost-effective to replenish B12 storage empirically 
for the duration rather than relying on homocysteine 
concentrations to diagnose B12 deficiency. Erythrocyte 
sedimentation rate, by way of physiological anaemia during 
pregnancy, is expected to be elevated but usually not to 
100 mm/hour. The mean peak ranges from 50–70 mm/hour 
depending on the gestational age.3 Thus, where it exceeds 
100 mm/hour it is important that active inflammation or 
infection is excluded. Similarly, while white cell count can 
rise up to 15–16 x 106/mL, the majority often do not exceed 
the non-pregnant reference range.4
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Ciprofloxacin and fever
Editor, – Adverse drug reactions are a common problem in 
medical practice and can present in a variety of ways. Fever 
is not an uncommon manifestation and may confuse the 
prescriber. 
We have recently seen three cases involving patients who 
were taking ciprofloxacin for febrile illnesses. While their 
conditions improved the patients remained febrile until they 
stopped the ciprofloxacin. We remind readers that fever is 







Editor, – I refer to the article 'Dealing with dizziness' 
(Aust Prescr 2005;28:94–7). I wish to recount a personal 
experience where, following dental treatment during 
which my head and neck were held in a rotated position 
for some time, I suffered an acute, but fortunately brief 
episode of severe dizziness and recall feeling 'queer' 
when given the all clear to sit up. Two days later I was 
confined to bed for 36 hours with an acute episode from 
which I recovered completely. Subsequent doppler 
studies revealed no evidence of compromised cerebral 
circulation. Is it possible that unusual posturing of one's 
head during dental therapy could be another cause of an 




Dr Mark Paine, the author of the article, comments:
The scenario is very suggestive of benign paroxysmal 
positional vertigo. The positioning of the patient during the 
dental treatment is very similar to the Hallpike positioning 
manoeuvre. While a bout of positional vertigo is usually 
brief, there may be after-effects causing persisting low grade 
dizziness which may last hours to days. To be certain about 
this diagnosis, it is essential to examine the patient during 
the episode.
Dr M. McCullough, Australian Dental Association, comments:
An acute feeling of dizziness following prolonged dental 
treatment is not uncommon in dental practice. Sudden 
changes in blood pressure following postural changes after 
prolonged periods in a supine dental chair may be 
responsible. Usually, if patient and dentist are aware of this 
possibility, then treatment procedures can be kept to shorter 
duration, with rest breaks during the procedure. 
Postural hypotension is unlikely to explain the episode 
occurring two days after the dental procedure. Possible 
explanations to consider include tooth extraction and 
subsequent haemorrhage with breakdown of haemostasis, 
infection and acute dental pain causing decreased nutrition 
or hydration.
'Statins' and muscle symptoms
Editor, – With 12 years of 'statins' under my personal belt I 
feel able to comment on the medicinal mishap 'Statins and 
muscle symptoms' (Aust Prescr 2005;28:102), particularly 
the checklist of muscle symptoms. My observations over 
many years since I first recognised the connection between 
my muscle pains and simvastatin, and briefly atorvastatin, 
lead me to assert that the pain:
■ is severe enough to wake you up
■ tends to be nocturnal, within 2–8 hours of the last 
dose, unless the statin is taken in the morning
■ is quickly and surprisingly easily relieved by a few 
contractions of the muscle concerned, or a walk to the 
bathroom – the ensuite may not be far enough
■ recurs in the same area of muscle, which is tender to 
touch and also on contraction
■ is never symmetrical – my right vastus lateralis was 
originally involved, and lately my left deltoid muscle.
Earlier I could control the symptoms by leaving out my 
daily dose of 10 mg on two days per week, but relief (that 
is unbroken sleep) sometimes took 24 hours. I tested this 
response perhaps dozens of times.
The insouciance of an overseas trip three months ago led 
me to taking a tablet every day. The result was persistent 
pain and weakness in the same muscle, and ultimately 
wasting, to the point where I was unable to step up with 
the right leg – a drastic disability in Europe.
After stopping the drug for two months, my thigh is nearly 
back to normal, but I can still feel the affected area. My 
lipids are not optimal now, but creatine kinase seems 
unaffected.
There seems little prospect of these adverse effects 
being reported to the Adverse Drug Reactions Advisory 
Committee because both my general practitioner and 
cardiologist attributed them (not so definitely of late) to 
my old age. I graduated in medicine 54 years ago. Having 
experienced both, I find old age much easier to take, so 
far, than the adverse effects I have experienced with the 
statins.
Peter J. Stobie
Emeritus ophthalmologist, Women's and Children's Hospital
Adelaide
 
